Tango Therapeutics, Inc. (TNGX) stock
TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)
Close on Nov 17, 2026Market cap $3.73BP/E –Yield –
Tango Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Tango Therapeutics
Tango Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?